• news.cision.com/
  • Impilo/
  • Impilo and Anders Larnholt form a partnership to create a new pan-European pharmaceutical platform

Impilo and Anders Larnholt form a partnership to create a new pan-European pharmaceutical platform

Report this content

Stockholm, December 15, 2020 - The Nordic investment company Impilo has partnered with Anders Larnholt, a pharma and healthcare executive and entrepreneur, to create a new platform; Mallax Pharmaceuticals AB* (“Mallax”). Mallax was founded in Sweden, with the aim of building a company with established pharmaceuticals and OTC products for customers and patients across Europe. 

“I’m very pleased to enter into a partnership with Impilo. They have a profound understanding of the healthcare sector and are long term investors. Sustainability, medical need, and profitable growth are cornerstones of Mallax’s strategy, and they will define how we operate and build our company”, says Anders Larnholt, Founder and CEO of Mallax.

“Anders Larnholt has an outstanding track record of building pharma and healthcare companies through acquisitions and partnerships, and we look forward to an exciting journey ahead. Our ambition is to invest significant capital and resources behind the right acquisition opportunities across Europe – with a wide size range for any individual deal between EUR 10m and EUR 300m”, says Magnus Edlund, Partner at Impilo.

For further information, please contact:
Anders Larnholt, Founder and CEO of Mallax Pharmaceuticals AB 
+46 76 677 6495

Magnus Edlund, Partner at Impilo and Board Member of Mallax Pharmaceuticals AB


About Impilo
Impilo is a Swedish investment company focused on long-term investments in healthcare companies active in pharmaceuticals, medical technology, healthcare services and other health-related areas. Impilo strives to increase value of its investments through long-term active ownership and aims to continuously generate returns for its stakeholders. Impilo has a portfolio of diversified investments and may hold an investment as long it deems it to be attractive (which may be for an indefinite period). Impilo's perspective is that the portfolio companies must contribute to a positive development in their fields and thus society in order to be successful long term. Impilo manages over SEK 3.5 billion in capital from leading Nordic and international investors. Larger investors include AP3 (The Third Swedish National Pension Fund), TryghedsGruppen and Goldman Sachs Asset Management. Learn more about Impilo at www.impilo.se.

About Anders Larnholt
Anders Larnholt has 20 years of pharma and healthcare experience from various executive positions, M&A, strategic advisory and board positions at Meda, Trimb Healthcare and other companies. In his latest role, he co-founded Trimb Healthcare that was sold to EQT and Karo pharma in 2019. Anders Larnholt has, in previous positions, completed 100+ pharma and healthcare deals with a total acquisition value of more than EUR 4 billion. Deals include European and global product acquisitions and licensing deals from international pharma companies such as Roche, Novartis, GSK, J&J as well as many mid-cap pharma companies. Numerous companies and other assets have also been acquired from private equity firms and private individuals. These initiatives and collaborations transformed previous companies from small Swedish firms to large corporations with thousands of employees in more than 50 countries.

Note: (*) Pending approval of the Mallax trademark